{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:52:18Z","timestamp":1776081138290,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00415-013-7115-8","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T13:51:21Z","timestamp":1384264281000},"page":"267-276","source":"Crossref","is-referenced-by-count":110,"title":["Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study"],"prefix":"10.1007","volume":"261","author":[{"name":"For the FIRST Study Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno","family":"Siever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra","family":"Bijarnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"von Rosenstiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davorka","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"issue":"24","key":"7115_CR1","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","volume":"277","author":"V Brinkmann","year":"2002","unstructured":"Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277(24):21453\u201321457","journal-title":"J Biol Chem"},{"key":"7115_CR2","unstructured":"European Medicines Agency (2011) Annex I. Summary of product characteristics. Gilenya (fingolimod). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002202\/WC500104528.pdf . Accessed 8 October 2012"},{"key":"7115_CR3","unstructured":"European Medicines Agency (2012) Revised summary of product characteristics. Gilenya (fingolimod). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2012\/04\/WC500125687.pdf . Accessed 8 October 2012"},{"key":"7115_CR4","unstructured":"US Food and Drug Administration (2010) Gilenya prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022527s002lbl.pdf . Accessed 8 October 2012"},{"key":"7115_CR5","unstructured":"US Food and Drug Administration (2012) Gilenya (fingolimod): revised US prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022527s008lbl.pdf . Accessed 8 October 2012"},{"issue":"(suppl 1)","key":"7115_CR6","first-page":"P01.133","volume":"78","author":"PA Calabresi","year":"2012","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan K, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, Malhotra M, von Rosenstiel P, Lublin FD (2012) Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): Results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study). Neurology 78(suppl 1):P01.133","journal-title":"Neurology"},{"issue":"5","key":"7115_CR7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402\u2013415","journal-title":"N Engl J Med"},{"issue":"5","key":"7115_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387\u2013401","journal-title":"N Engl J Med"},{"issue":"3","key":"7115_CR9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","volume":"5","author":"L Koyrakh","year":"2005","unstructured":"Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transpl 5(3):529\u2013536","journal-title":"Am J Transpl"},{"issue":"11","key":"7115_CR10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G, Montalban X, O\u2019Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355(11):1124\u20131140","journal-title":"N Engl J Med"},{"key":"7115_CR11","unstructured":"ICH harmonized tripartite guideline\u2013guideline for good clinical practice: E6(R1). Geneva: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf . Accessed 8 October 2012"},{"key":"7115_CR12","unstructured":"Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire F. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html . Accessed 8 October 2012"},{"key":"7115_CR13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"C Polman","year":"2005","unstructured":"Polman C (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol 58:840\u2013846","journal-title":"Ann Neurol"},{"key":"7115_CR14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"issue":"Suppl 4","key":"7115_CR15","first-page":"55","volume":"18","author":"J DiMarco","year":"2012","unstructured":"DiMarco J, O\u2019Connor P, Cohen J, Reder A, Zhang-Auberson L, Tang D, Collins W, Kappos L (2012) Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Mult Scler 18(Suppl 4):55\u2013227","journal-title":"Mult Scler"},{"issue":"5","key":"7115_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00228-007-0448-4","volume":"64","author":"JM Kovarik","year":"2008","unstructured":"Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR, Schmouder RL (2008) The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol 64(5):457\u2013463","journal-title":"Eur J Clin Pharmacol"},{"key":"7115_CR17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2012.09.009","volume":"23","author":"D Ontaneda","year":"2012","unstructured":"Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA (2012) Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 23:167\u2013172","journal-title":"J Neurol Sci"},{"key":"7115_CR18","unstructured":"US Food and Drug Administration (2012) Gilenya (fingolimod): Drug safety communication\u2013revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm303192.htm . Accessed 8 October 2012"}],"updated-by":[{"DOI":"10.1007\/s00415-014-7280-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-013-7115-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-013-7115-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-013-7115-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T19:14:48Z","timestamp":1551208488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-013-7115-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["7115"],"URL":"https:\/\/doi.org\/10.1007\/s00415-013-7115-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-014-7280-4","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]}}}